TransMedics shines with Q1 EPS at $0.35, and sales soared to $96.9 million. Fiscal 2024 revenue outlook raised to $390 million-$400 million. Analysts hail TransMedics' organic growth and strong market position, praising its innovative solutions and promising prospects.
Conduent impresses with Q1 FY24 earnings, surpassing analyst expectations. Despite a slight sales dip of 0.1% Y/Y to $921 million, the company outperformed consensus estimates. Notably, total operating costs and expenses saw a significant 14.6% decline to $794 million.